CORCencora

Healthcare

$330.93+4.2% 1Y

$330.93

$252.1652 weeks$373.25

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.

1 good, 1 to watch, 1 neutral

What the price assumes~+2% a year

Priced for ~2% a year FCF growth. The price demands less than its three-year revenue growth of 9% a year, expectations look modest.

Vs its own P/E rangedearer than 78% of its own historyderived

Expensive vs its own history: P/E 24.6 vs a 18.1 median over 37 quarters (+36% vs median).

Vs sector (EV/EBIT)23.7×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)middle of the market

FCF yieldbetter than 67% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What COR's price assumes

Cencora trades at 24.6× earnings against 27.9× for the median Healthcare name, cheaper than its own group.

24.6

Trailing P/E · Healthcare median 27.9 · cheaper than the typical name in its group

Price / sales: 0.19
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 6.4%
Free cash flow yield · Healthcare median 4.3%
Growth the price implies: +2.3%
Growth the price implies · The price pays for +2.3% free cash flow growth a year for a decade; the business has delivered +13% a year over the last three.

Details›

Price / booktoday's price, trailing year to Jun 30, 2026: 20.7
EV / EBIToperating margin 0.91%: the multiple describes the denominator: not meaningful
EV / salestoday's price, trailing year to Jun 30, 2026: 0.22
Healthcare median P/E503 names: 27.9
Free cash flow, trailing twelve months: $4.06B
Market capitalisation190.8 million shares, counted Jul 31, 2026: $63.2B
3-year revenue growth: +9.4%
3-year free cash flow growth: +13%

What the market has paid for these earnings: 37 quarters of its own multiple × $13.47 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$198.10
Its own P/E history, median	$243.95
Its own P/E history, upper quartile	$323.51
52-week range	$252.16 – $373.25
Today	$330.93

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.